Stem cells for wound healing

Patent metadata

Field	Value
Publication number	US-10967006-B2
Application number	US-201615043171-A
Country	US
Kind code	B2
Filing date	Feb 12, 2016
Priority date	Jan 21, 2016
Publication date	Apr 6, 2021
Grant date	Apr 6, 2021

Abstract

The present invention provides a method for treating wounds by applying cells as described in this application. In one aspect the method provides treatment for cutaneous wounds. In general embodiments the cells are delivered to the wound without being attached to a functionalized substrate in the delivery vehicle.

First claim

What is claimed is:

1. A method to promote wound healing of an ulcer in a subject by administering cells (I) in an effective amount and for a time sufficient to promote the wound healing in the ulcer, wherein the cells (I) are not delivered from a functionalized substrate, wherein the cells (I) are non-embryonic non-germ cells that express CD90 and oct4 or telomerase, are not transformed, are not tumorigenic, and have a normal karyotype.

2. The method of claim 1 , wherein the cells (I) express telomerase.

3. The method of either of claims 1 or 2 , wherein the cells (I) can differentiate into at least one cell type of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages.

4. The method of claim 3 , wherein the cells (I) can differentiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages.

5. The method of claims 1 or 2 , wherein the ulcer is selected from the group consisting of dermal ulcers found in feet, hand, legs, or arms and venous leg ulcers.

6. The method of claim 5 , wherein the dermal ulcer is caused by a disease selected from the group consisting of diabetes and sickle-cell anemia.

7. The method of either of claims 1 or 2 , wherein the cells (I) are not genetically manipulated.

8. The method of either of claims 1 or 2 , wherein the cells (I) are derived from bone marrow.

9. The method of either of claims 1 or 2 , wherein the cells (I) are derived from a human.

10. The method of either of claims 1 or 2 , wherein the subject is human.

11. The method of claim 1 , wherein the wound is caused by insufficient circulation of peripheral blood or lymphatic system.

12. The method of either of claims 1 or 2 , wherein the cells (I) are administered to the wound topically.

13. The method of either of claims 1 or 2 , wherein the cells (I) are delivered subcutaneously.

14. The method of either of claims 1 or 2 , wherein the cells (I) are administered to the wound by injection.

15. The method of either of claims 1 or 2 , wherein the cells (I) are administered in liquid cell suspension.

16. The method of either of claims 1 or 2 , wherein the cells (I) are administered to the wound using a reservoir.

17. The method of either of claims 1 or 2 , wherein the cells (I) are allogeneic.

Assignees

• Abt Holding Co
• Univ Leuven Kath

Inventors

• Luttun Aernout
• Deans Robert J

Classifications

• C12N5/0607

  Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N5/0696) · CPC title

• A01K2267/03

  Animal model, e.g. for test or diseases · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• A01K2227/105

  Murine · CPC title

• A01K2207/12

  Animals modified by administration of exogenous cells · CPC title